Prostate Cancer Advisor Videos - Cancer Therapy Advisor

Prostate Cancer Advisor Videos

Chapter 1

Targeted Agents

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.

Chapter 2

Targeted Agents (cont.)

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss radium-223 in treatment of mCRPC with bone metastases.

Chapter 3

Radium-223

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss radium-223 in treatment of mCRPC with bone metastases.

Chapter 4

Chemotherapy

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the role of cytotoxic chemotherapy in treatment of castration resistant prostate cancer and metastatic castration resistant prostate cancer.

Chapter 5

Immunotherapy

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss immunotherapy approaches to treatment of metastatic castration resistant prostate cancer.

Chapter 6

Treatment Sequencing

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss optimal sequencing of therapies in metastatic castration resistant prostate cancer.

Chapter 7

Androgen Deprivation Therapy

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss androgen deprivation therapy in advanced/metastatic prostate cancer.

Chapter 8

Duration of Androgen Deprivation Therapy

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss optimal duration of androgen deprivation in the treatment of high-risk and very high-risk locally advanced prostate cancer.

Chapter 10

Androgen Deprivation Therapy Resistance

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss resistance to androgen deprivation therapy in men with prostate cancer.

Chapter 11

Androgen Deprivation Therapy and Radiation

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the use of radiation with androgen deprivation therapy in men with prostate cancer.

Chapter 12

Predictions for the Future

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss their predictions for advances in the treatment of men with prostate cancer in next five years.